|Bid||8.20 x 3200|
|Ask||8.49 x 3200|
|Day's Range||8.28 - 8.53|
|52 Week Range||6.78 - 11.45|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 27, 2017|
|1y Target Est||10.17|
Key Insights Given the large stake in the stock by institutions, Teva Pharmaceutical Industries' stock price might be...
As much as we'd enjoy a stock market that never declined, stocks can and do move in both directions. Last year, all three major U.S. stock indexes tumbled into respective bear markets and produced their worst returns since the financial crisis. Despite 39 official stock market corrections in the benchmark S&P 500 since the beginning of 1950, all but the current decline eventually gave way to a bull market rally that took the broader market to new highs.
TEL AVIV, Israel, March 13, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: